A Phase 1/2 Open-Label, Single-Ascending-Dose Study of EN-374, a Helper-Dependent Adenoviral-Based Gene Therapy, in Participants with X-Linked Chronic Granulomatous Disease
Latest Information Update: 24 Aug 2026
At a glance
- Drugs Gene therapies (Primary)
- Indications Chronic granulomatous disease
- Focus Adverse reactions
- Sponsors Ensoma
Most Recent Events
- 21 Aug 2026 Status changed from recruiting to active, no longer recruiting.
- 08 May 2026 According to Ensoma media release, the data from the trial will be presented at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting, 2026.
- 10 Dec 2025 According to Ensoma media release, pediatric participants would be enrolled in a dose-expansion cohort, after completion of the adult cohorts.